Jim Cramer's Stop Trading: Buy GW Pharmaceuticals, Not ConAgra Foods

NEW YORK (TheStreet) -- After rallying higher on Tuesday following positive reports about its cannabinoid epilepsy drug, Epidiolex, shares of GW Pharmaceuticals (GWPH) are lower by roughly 5% on Wednesday after the company announced a secondary offering. 

On CNBC's "Cramer's Stop Trading" segment, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, said investors want to buy the stock on its secondary offering. 

Why? Well, it's simple. Cramer reasoned that GW Pharmaceuticals is the "only really legitimate" marijuana company for investors to put their money in. The British company is also doing very well, he added. 

However, he did not feel the same toward ConAgra Foods (CAG), which reported "a horrible quarter."

According to the CEO, the dividend is still safe, Cramer said. But its private label brands are doing "poorly," consumer volume was weak, and the numbers for Chef Boyardee were "terrible." 

He concluded that canned foods are simply not selling well, because they do not give off the impression of natural and organic food.

-- Written by Bret Kenwell in Petoskey, Mich.

15 Minutes of Every Hour Meeting Are a Waste of Time

Apple Unveils Latest iMac, Starting at $1,099

The U.K. Is 'Pound'-ing the Pavement With Chinese Business Deals

Citigroup Looks Like a Smart Hedge as Interest Rates Remain Low

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.

If you liked this article you might like

Snap, Kinder Morgan, Iconix Brands: 'Mad Money' Lightning Round

Stay Focused on the Green Lights: Cramer's 'Mad Money' Recap (Wed 8/30/17)

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Snap-On, Teekay Shipping, FLIR Systems, GW Pharmaceuticals: 'Mad Money' Lightning Round

Time to Raise Some Cash: Cramer's 'Mad Money' Recap (Tuesday 8/1/17)